ZA201706323B - Anti-pvrig antibodies and methods of use - Google Patents

Anti-pvrig antibodies and methods of use

Info

Publication number
ZA201706323B
ZA201706323B ZA2017/06323A ZA201706323A ZA201706323B ZA 201706323 B ZA201706323 B ZA 201706323B ZA 2017/06323 A ZA2017/06323 A ZA 2017/06323A ZA 201706323 A ZA201706323 A ZA 201706323A ZA 201706323 B ZA201706323 B ZA 201706323B
Authority
ZA
South Africa
Prior art keywords
methods
pvrig antibodies
pvrig
antibodies
Prior art date
Application number
ZA2017/06323A
Other languages
English (en)
Inventor
White Mark
Kumar Sandeep
Chan Christopher
Liang Spencer
STAPLETON Lance
w drake Andrew
Gozlan Yosi
Vaknin Iian
Sameah-Greenwald Shirley
Dassa Liat
Tiran Zohar
S Cojocaru Gad
Presta Leonard
Theolis Richard
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201706323(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of ZA201706323B publication Critical patent/ZA201706323B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
ZA2017/06323A 2015-02-19 2017-09-19 Anti-pvrig antibodies and methods of use ZA201706323B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US201562235823P 2015-10-01 2015-10-01
PCT/US2016/018809 WO2016134333A1 (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Publications (1)

Publication Number Publication Date
ZA201706323B true ZA201706323B (en) 2020-05-27

Family

ID=55453315

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06323A ZA201706323B (en) 2015-02-19 2017-09-19 Anti-pvrig antibodies and methods of use

Country Status (22)

Country Link
US (8) US10227408B2 (enExample)
EP (4) EP3653221B1 (enExample)
JP (2) JP7115856B2 (enExample)
KR (2) KR20240090732A (enExample)
CN (2) CN115350275A (enExample)
AU (3) AU2016219835B2 (enExample)
CA (1) CA2976926A1 (enExample)
CY (2) CY1122970T1 (enExample)
DK (3) DK3653221T5 (enExample)
ES (3) ES2806800T3 (enExample)
HR (3) HRP20200572T1 (enExample)
HU (3) HUE061084T2 (enExample)
IL (2) IL254039B2 (enExample)
LT (3) LT3653221T (enExample)
MX (2) MX374853B (enExample)
PL (3) PL3653221T3 (enExample)
PT (3) PT3653221T (enExample)
RU (1) RU2732042C2 (enExample)
SG (1) SG11201706583PA (enExample)
SI (2) SI3258951T1 (enExample)
WO (1) WO2016134333A1 (enExample)
ZA (1) ZA201706323B (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3243494B2 (ja) 1999-05-18 2002-01-07 独立行政法人産業技術総合研究所 チオフェン水素化脱硫用触媒及びその製造方法
JP5641508B2 (ja) * 2010-02-23 2014-12-17 国立大学法人 東京大学 樹状細胞免疫受容体刺激剤
MY178233A (en) 2013-12-20 2020-10-07 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
PL3653221T3 (pl) 2015-02-19 2022-12-19 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
US11078278B2 (en) * 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
HK1252696A1 (zh) * 2015-08-28 2019-05-31 艾利妥 抗siglec-7抗体及其使用方法
AU2016315892B2 (en) * 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
HRP20200189T1 (hr) 2016-08-17 2020-05-01 Compugen Ltd. Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije
AU2017331362B2 (en) 2016-09-23 2025-01-23 Fred Hutchinson Cancer Center TCRs specific for minor histocompatibility (H) antigen HA-1 and uses thereof
AU2018234830B2 (en) 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
KR102641269B1 (ko) 2017-05-24 2024-02-26 이펙터 테라퓨틱스, 인크. 개선된 항종양 면역 반응을 위한 조성물 및 방법
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
AU2018304173A1 (en) 2017-07-17 2020-01-30 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
WO2019033057A1 (en) 2017-08-11 2019-02-14 Fred Hutchinson Cancer Research Center SPECIFIC BRAF TCR AND USES THEREOF
WO2019051128A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF
CN111065409A (zh) 2017-09-06 2020-04-24 弗雷德哈钦森癌症研究中心 Strep-tag特异性结合蛋白及其用途
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019075359A1 (en) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS AND METHODS OF USE
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
US10738125B2 (en) 2018-03-13 2020-08-11 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
CA3097679A1 (en) 2018-05-09 2019-11-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin4
AU2019278875A1 (en) 2018-05-31 2020-10-22 Glyconex Inc. Therapeutic antibodies binding to biantennary Lewis B and Lewis Y antigens
BR112020024249A2 (pt) * 2018-06-01 2021-03-02 Compugen Ltd. anticorpo biespecífico anti-pvrig/anti-tigit, composição, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, métodos para produzir um anticorpo biespecífico anti-pvrig/anti-tigit, para ativação de células t de um paciente, para ativação de células t citotóxicas de um paciente, para ativação de células nk de um paciente, para ativação de células t gama delta de um paciente, para ativação de células th1 de um paciente, para diminuir ou eliminar o número de células e/ou a atividade de pelo menos uma das células t reguladoras em um paciente, para aumentar a produção de interferon-gama e/ou a secreção de citocinas pró-inflamatórias em um paciente e para tratamento de câncer em um paciente, anticorpo anti-pvrig, anticorpo anti-tigit, e, vetor de expressão.
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
BR112021000727A2 (pt) * 2018-07-20 2021-04-13 Surface Oncology, Inc. Composições anti-cd112r e métodos
MX2021001938A (es) 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
CN113164593A (zh) * 2018-09-14 2021-07-23 金德雷德生物科学股份有限公司 兽用抗il4受体抗体
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US20240165232A1 (en) 2018-09-24 2024-05-23 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
BR112021005769A2 (pt) 2018-09-25 2021-07-06 Harpoon Therapeutics Inc proteínas de ligação a dll3 e métodos de uso
KR20210102231A (ko) 2018-11-09 2021-08-19 프레드 헛친슨 켄서 리서치 센터 메소텔린에 특이적인 t 세포 수용체 및 면역요법에서의 그의 용도
SG11202106483WA (en) 2018-12-19 2021-07-29 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
JP7492522B2 (ja) * 2019-02-06 2024-05-29 パイオニア イミュノセラピューティクス インコーポレイテッド 抗ｔｒｅｍ１抗体及び関連方法
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
GB2613715B (en) 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
MX2021010837A (es) 2019-03-11 2021-10-14 Fred Hutchinson Cancer Center Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.
KR20220041881A (ko) 2019-07-29 2022-04-01 컴퓨젠 엘티디. 항-pvrig 항체 제제 및 이의 용도
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
JP7737978B2 (ja) 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Ｗｔ－１に特異的なｔ細胞免疫療法
WO2021042000A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
WO2021091605A1 (en) 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4058062A4 (en) * 2019-11-15 2023-11-08 Surface Oncology, Inc. COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
CN115003333A (zh) * 2020-03-13 2022-09-02 江苏恒瑞医药股份有限公司 Pvrig结合蛋白及其医药用途
TW202208422A (zh) 2020-06-24 2022-03-01 美商維爾生物科技股份有限公司 經工程化之b型肝炎病毒中和抗體及其用途
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
TW202216778A (zh) * 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN116724053A (zh) 2020-09-24 2023-09-08 弗雷德哈钦森癌症中心 靶向sox2抗原的免疫治疗
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022061791A1 (zh) * 2020-09-25 2022-03-31 苏州大学 肿瘤特异性 t 细胞的检测方法
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
EP4232822A2 (en) * 2020-10-26 2023-08-30 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN112433055A (zh) * 2020-11-04 2021-03-02 上海药明生物技术有限公司 一种基于报告基因方法检测pvrig抗体的生物学活性的方法
WO2022132836A2 (en) 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024504167A (ja) 2021-01-26 2024-01-30 ヴィア・バイオテクノロジー・インコーポレイテッド Ｂ型肝炎ウイルス感染を処置するための抗体組成物および方法
WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
EP4284516A1 (en) 2021-01-28 2023-12-06 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
KR20230144596A (ko) * 2021-02-09 2023-10-16 상하이 준스 바이오사이언스 컴퍼니 리미티드 항 cd112r 항체 및 그의 용도
EP4291580A1 (en) 2021-02-11 2023-12-20 Nectin Therapeutics Ltd. Antibodies against cd112r and uses thereof
CN115925917A (zh) * 2021-03-08 2023-04-07 合肥天港免疫药物有限公司 抗pvrig蛋白抗体或抗体片段及其用途
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ
CN115010800B (zh) * 2021-06-10 2024-08-06 百奥赛图(北京)医药科技股份有限公司 Pvrig基因人源化非人动物的构建方法及应用
EP4363450A1 (en) * 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
MX2024000674A (es) 2021-07-13 2024-02-07 BioNTech SE Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion.
US20250250319A1 (en) 2021-07-15 2025-08-07 Fred Hutchinson Cancer Center Chimeric transmembrane polypeptides comprising a tgf beta receptor extracellular domain, a transmembrane domain and an interleukin receptor 2 intracellular signalling domain and its use in therapy
EP4378954A4 (en) 2021-07-30 2025-05-21 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
CA3231553A1 (en) 2021-09-15 2023-03-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
WO2023040940A1 (zh) * 2021-09-15 2023-03-23 江苏恒瑞医药股份有限公司 Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
CN117940453A (zh) 2021-09-15 2024-04-26 江苏恒瑞医药股份有限公司 特异性结合pd-1的蛋白及其医药用途
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CN115819582A (zh) * 2021-12-24 2023-03-21 合肥天港免疫药物有限公司 Pvrig的抗体或其抗原结合片段及其应用
CN114644711B (zh) * 2022-03-07 2025-03-04 南京诺艾新生物技术有限公司 重组抗人pvrig抗体及应用
EP4493195A1 (en) 2022-03-15 2025-01-22 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
EP4245374A3 (en) * 2022-03-18 2024-07-10 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN116925222A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗pvrig抗体、其药物组合物及用途
CN116925233A (zh) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
TW202415678A (zh) * 2022-06-14 2024-04-16 比利時商艾伯霖克斯公司 靶向ｔ細胞受體的免疫球蛋白單可變結構域
WO2024026496A1 (en) 2022-07-28 2024-02-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
AR130172A1 (es) * 2022-08-10 2024-11-13 Beigene Ltd Anticuerpos anti-pvrig y métodos de uso
JP2025529238A (ja) * 2022-08-31 2025-09-04 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗ｐｖｒｉｇ抗体及びその使用
WO2024098980A1 (en) * 2022-11-10 2024-05-16 Huahui Health Ltd. Anti-cd112r antibodies and use thereof
IL321098A (en) 2022-12-14 2025-07-01 Astellas Pharma Europe Bv Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors
EP4644419A1 (en) 2022-12-30 2025-11-05 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Antibody targeting cd112r or antigen-binding fragment thereof and use thereof
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
TW202502812A (zh) * 2023-06-06 2025-01-16 大陸商上海藥明生物技術有限公司 抗pvrig抗體及其用途
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
CN117964762B (zh) * 2023-12-22 2024-12-24 华润生物医药有限公司 抗pvrig抗体及其用途
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload
CN119193693B (zh) * 2024-08-06 2025-06-13 湖南农业大学 重组质粒及其制备方法、蛋白组合物、用途、疫苗、组合疫苗
CN120058919B (zh) * 2025-04-29 2025-07-18 浙江大学杭州国际科创中心 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20040002117A1 (en) 1998-02-12 2004-01-01 Hogan Patrick G. Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
CA2363684A1 (en) 1999-03-05 2000-09-08 Incyte Pharmaceuticals, Inc. Human secretory proteins
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
US20030224379A1 (en) 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
AU2002305539A1 (en) 2001-05-09 2002-11-18 Yale University Toll/interleukin-1 receptor adaptor protein (tirap)
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1539228B1 (en) 2002-09-11 2010-12-29 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004058805A2 (en) * 2002-12-26 2004-07-15 Asahi Kasei Pharma Corporation T cell activating gene
WO2004091658A1 (en) 2003-04-04 2004-10-28 Genentech, Inc. High concentration antibody and protein formulations
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AR047372A1 (es) 2004-01-09 2006-01-18 Pfizer Anticuerpos contra madcam
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7622265B2 (en) 2005-02-22 2009-11-24 Genentech, Inc. Methods and compositions for modulating prostasin
JP2008544746A (ja) 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
US20070254339A1 (en) 2006-04-13 2007-11-01 West James W Tetramerizing polypeptides and methods of use
US20070243584A1 (en) 2006-04-13 2007-10-18 West James W Tetramerizing polypeptides and methods of use
US20090318376A1 (en) 2006-06-15 2009-12-24 Korea Research Institute Of Bioscience And Biotechnology High Throughput Screening Method of Binding Inhibitor Between caspase3 and XIAP and Binding Inhibitor Screened Thereby
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
CA2666249A1 (en) * 2006-10-06 2008-04-17 Takeda Pharmaceutical Company Limited Agent for preventing/treating cancer
WO2009017679A2 (en) * 2007-07-31 2009-02-05 Merck & Co., Inc. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US20110236903A1 (en) 2008-12-04 2011-09-29 Mcclelland Michael Materials and methods for determining diagnosis and prognosis of prostate cancer
JP5725508B2 (ja) 2009-03-25 2015-05-27 国立大学法人東北大学 Ｌｈ型二重特異性抗体
US20110217297A1 (en) 2010-03-03 2011-09-08 Koo Foundation Sun Yat-Sen Cancer Center Methods for classifying and treating breast cancers
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
PT2643019T (pt) 2010-11-24 2019-04-23 Lexicon Pharmaceuticals Inc Anticorpos para notum pectinacetilesterase
WO2012129488A2 (en) 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
EP2710147A1 (en) 2011-05-18 2014-03-26 Rheinische Friedrich-Wilhelms-Universität Bonn Molecular analysis of acute myeloid leukemia
CA2840946A1 (en) 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
TW201323440A (zh) 2011-10-24 2013-06-16 Abbvie Inc 抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
JP2015520192A (ja) 2012-06-06 2015-07-16 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｈｉｐｐｏ経路を調節する結合剤およびその使用
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
MY183503A (en) 2013-07-16 2021-02-23 Genentech Inc Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN106132989B (zh) 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
MA40437A (fr) 2014-07-16 2017-05-24 Hoffmann La Roche Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
JP6857603B2 (ja) 2014-11-18 2021-04-14 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｃｄ１４７抗体、方法及び使用
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
PL3653221T3 (pl) 2015-02-19 2022-12-19 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
WO2016134335A2 (en) 2015-02-19 2016-08-25 Compugen Ltd. Pvrig polypeptides and methods of treatment
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
AU2016315892B2 (en) 2015-09-02 2023-06-15 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for modulating T-cell mediated immune response
SMT202500003T1 (it) 2015-09-25 2025-03-12 Hoffmann La Roche Anticorpi anti-tigit e procedimenti di utilizzo
HUE058755T2 (hu) 2015-10-01 2022-09-28 Potenza Therapeutics Inc Anti-tigit antigénkötõ proteinek és felhasználásuk módszerei
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2018017864A2 (en) 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
HRP20200189T1 (hr) 2016-08-17 2020-05-01 Compugen Ltd. Anti-tigit antitijela, anti-pvrig antitijela i njihove kombinacije
KR102595080B1 (ko) 2016-12-23 2023-10-30 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 포유류 세포 배양에서 항체 생산성을 증강시키고 하류 제제화 프로세스 동안 응집을 최소화하기 위한 개선된 방법, 및 그로부터 수득된 안정한 항체 제제
CA3061235A1 (en) 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
MX2019014265A (es) 2017-06-01 2020-08-03 Compugen Ltd Tratamientos conjuntos triples con anticuerpos.
MA51747A (fr) 2018-02-08 2020-12-16 Amgen Inc Formulation d'anticorps pharmaceutique à ph faible
WO2021091605A1 (en) 2019-11-04 2021-05-14 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
WO2022222125A1 (zh) 2021-04-23 2022-10-27 京东方科技集团股份有限公司 一种解锁控制方法、装置、电子设备和计算机可读存储介质

Also Published As

Publication number Publication date
MX2020009461A (es) 2021-02-17
EP3258951A1 (en) 2017-12-27
JP2022106783A (ja) 2022-07-20
EP3653221B1 (en) 2022-08-03
EP3653221A1 (en) 2020-05-20
CA2976926A1 (en) 2016-08-25
RU2017132214A3 (enExample) 2019-08-28
RU2017132214A (ru) 2019-03-19
LT3295951T (lt) 2020-09-25
IL304117A (en) 2023-09-01
US9714289B2 (en) 2017-07-25
KR102669294B1 (ko) 2024-05-23
US20250333503A1 (en) 2025-10-30
US11795220B2 (en) 2023-10-24
AU2016219835A1 (en) 2017-09-14
ES2929293T3 (es) 2022-11-28
US20240101669A1 (en) 2024-03-28
WO2016134333A1 (en) 2016-08-25
US11623955B2 (en) 2023-04-11
LT3258951T (lt) 2020-05-11
EP3295951A1 (en) 2018-03-21
CY1122970T1 (el) 2021-10-29
CN107580500B (zh) 2023-05-30
EP3258951B1 (en) 2020-01-29
CN107580500A (zh) 2018-01-12
SI3258951T1 (sl) 2020-07-31
ES2806800T3 (es) 2021-02-18
US20180244774A1 (en) 2018-08-30
HRP20221284T1 (hr) 2022-12-23
HRP20200572T1 (hr) 2020-08-21
DK3258951T3 (da) 2020-04-06
US20200148769A1 (en) 2020-05-14
AU2016219835B2 (en) 2020-12-03
CY1123259T1 (el) 2021-12-31
DK3295951T3 (da) 2020-07-20
US20170081408A1 (en) 2017-03-23
SI3295951T1 (sl) 2020-10-30
IL254039A0 (en) 2017-10-31
US10227408B2 (en) 2019-03-12
EP3295951B1 (en) 2020-04-22
LT3653221T (lt) 2022-11-10
CN115350275A (zh) 2022-11-18
PL3653221T3 (pl) 2022-12-19
HUE049791T2 (hu) 2020-10-28
HK1247569A1 (en) 2018-09-28
ES2786651T3 (es) 2020-10-13
HUE061084T2 (hu) 2023-05-28
RU2732042C2 (ru) 2020-09-10
PL3295951T3 (pl) 2020-10-05
EP4129320A1 (en) 2023-02-08
RU2020128686A (ru) 2020-10-13
SG11201706583PA (en) 2017-09-28
HUE049032T2 (hu) 2020-08-28
JP7115856B2 (ja) 2022-08-09
US20170029504A1 (en) 2017-02-02
WO2016134333A9 (en) 2017-02-02
AU2024202336A1 (en) 2024-05-16
US11220542B2 (en) 2022-01-11
KR20240090732A (ko) 2024-06-21
JP2018512443A (ja) 2018-05-17
KR20170137067A (ko) 2017-12-12
DK3653221T5 (da) 2024-08-26
PT3653221T (pt) 2022-11-08
HK1247568A1 (en) 2018-09-28
IL254039B2 (en) 2023-12-01
AU2020264349B2 (en) 2024-05-02
MX374853B (es) 2025-03-06
PT3295951T (pt) 2020-07-21
IL254039B1 (en) 2023-08-01
US20160244521A1 (en) 2016-08-25
AU2020264349A1 (en) 2020-12-03
US10351625B2 (en) 2019-07-16
US12312404B2 (en) 2025-05-27
PL3258951T3 (pl) 2020-07-27
PT3258951T (pt) 2020-08-18
DK3653221T3 (da) 2022-10-24
HRP20201066T1 (hr) 2021-02-05
US20210188974A1 (en) 2021-06-24
MX2017010667A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
IL304117A (en) Anti-pvrig antibodies and methods of use
IL259495A (en) Antibodies and methods for using them
IL257636A (en) Anti-tigit antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
SG11201803567XA (en) Anti-siglec-9 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
IL259681A (en) New antibodies against claudin and methods of using them
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
SG11201703426PA (en) Anti-pdgf-b antibodies and methods of use